Commit To Buy Omeros At $10, Earn 26.6% Annualized Using Options

Omeros Corp (OMER) options traders can sell a May 2026 $10 put for a $1 premium, implying a 26.6% annualized return but only resulting in share ownership if the stock falls ~35.1% and the option is exercised—leading to an effective cost basis of $9.00 before commissions. The stock trades at $15.34 and the trailing-12-month volatility is 146% (based on 249 trading days), highlighting significant price risk and underscoring that the sole upside for the put seller is the collected premium unless assigned.

Analysis

Market structure: The current setup benefits volatility sellers and market-makers capturing the 26.6% annualized premium on OMER May 2026 $10 puts; institutional cash‑secured put buyers who want entry at ~$9 also win if assignment occurs. Shareholders, retail call holders and unsecured creditors are the losers in a downside-biased outcome because OMER’s 146% trailing vol signals wide tails and frequent gap risk. Options flow likely raises implied volatility and fees for NDAQ via trading volumes, while hedging demand tightens bid/offer spreads.

Risk assessment: Tail risks are clinical failure, regulatory hold, or a refinancing/dilution event that can instantly move OMER >35% (the put break-even stated) — these are low-probability but would be high‑impact for put sellers. On days-to-weeks, gamma and IV spikes around news can swamp premium; over 3–12 months cash runway and funding markets determine equity dilution risk. Hidden dependencies include retail gamma squeezes and biotech ETF flows that can amplify moves; catalysts that will flip the trade are FDA/phase readouts, partner deals, or an equity raise.

Trade implications: For cash‑secured sellers who want a defined entry, sell May‑2026 OMER $10 puts sized to 0.5–1.5% of portfolio but hedge with a $5–$6 long put (create a put‑spread) to cap downside; target realized annualized carry >15% after hedges. If directional bullish, buy OMER shares up to 0.5–1% at price < $12 with a 40% stop, or buy 12–18 month outcalls if you want asymmetric upside and can tolerate >150% IV. Avoid naked short volatility >2% portfolio unless you have cash to absorb full assignment.

Contrarian angles: The market may be underpricing the option-seller’s desire to own shares at an effective $9 cost while overpricing continuous tail risk — ideal for disciplined cash‑secured put spreads, not naked puts. Historical parallels (biotech post-readout IV spikes) show selling into elevated IV with defined hedges often outperforms, but assignment risk plus dilution can create multi-month pain. Unintended consequence: aggressive put selling could leave funds stuck with concentrated OMER exposure into a capital raise, so cap position sizes and require immediate rebalancing triggers.

Key Decisions for Investors

• Establish a cash‑secured put‑spread: sell OMER May‑2026 $10 puts and buy May‑2026 $6 puts sized to 0.5–1.5% of portfolio (max loss = $4 minus net premium). Aim to capture ~15–25% nominal annualized return after the hedge; close if implied vol drops >40% or premium falls 50%.
• If willing to own the equity, set a limit to buy OMER shares at <= $12 for 0.5–1.0% portfolio exposure; use a hard stop‑loss at -40% and exit or hedge if company announces an equity raise within 90 days.
• Avoid naked short OMER puts larger than 1% of portfolio; if selling naked, require cash collateral equal to strike*shares and reduce size immediately if OMER price < $11 or if implied vol > 200%.
• Monitor three catalysts on a 0–180 day horizon: (1) any clinical/FDA readouts or press releases (trade size +/− 50% within 7 days), (2) cash runway / SEC filings signaling dilution (sell/hedge if S-3 or shelf appears), and (3) IV mean reversion (enter premium sells only when IV > 140% and exit if IV < 100%).